Mohanty 1999.

Methods	Site not described Randomization not described Blinding: double blinded
Participants	Geographic region: NR Study setting: clinic N = 75 Baseline modified Boyarsky: NR Baseline prostate volume: SR 28.78 mL; placebo 29.89 mL Mean age (range): NR (40 to 90) years Race: NR Diagnostic criteria: BPH grades I or II; symptomatic; without surgical indication; took no BPH drug treatment for last 30 days.
Interventions	Control: matching placebo, 1 capsule twice daily Treatment: SR, 1 capsule twice daily Study duration: 2 months Lost to follow‐up: SR n = 2; placebo n = 0
Outcomes	Modified Boyarsky (range 0 to 27, with a higher score indicating worse symptoms) Frequency Nocturia Peak urine flow Residual volume Prostate size (ultrasound) Adverse events
Notes	Exclusions: men with prostate conditions other than BPH (carcinoma of the prostate, infective prostatitis); serious renal, hepatic and cardiac conditions.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	not described
Allocation concealment (selection bias)	Unclear risk	not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	adequate
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	not mentioned
Incomplete outcome data (attrition bias) All outcomes	Low risk	adequate
Selective reporting (reporting bias)	Low risk	none
Other bias	Unclear risk	no description of baseline comparability of the two arms other than for age